Erika Jones - 13 Feb 2023 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Officer Title: Vice President, Finance and Corporate Controller
Signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
Issuer symbol
BDTX
Transactions as of
13 Feb 2023
Net transactions value
$0
Form type
4
Filing time
15 Feb 2023, 15:11:10 UTC
Previous filing
17 Feb 2022
Next filing
15 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDTX Common Stock Award $0 +5,075 +100% $0.000000 10,150 13 Feb 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDTX Stock Option (Right to Buy) Award $0 +60,000 $0.000000 60,000 13 Feb 2023 Common Stock 60,000 $2.92 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was previously granted performance-based Restricted Stock Units ("RSUs"). The vesting of 35% of the RSUs was subject to the achievement of certain performance criteria. As of the transaction date, the performance criteria were met, resulting in the vesting of 1,776 RSUs, with the remainder vesting on August 15, 2023, subject to the grantee's continuous service through such vesting date.
F2 25% of the shares subject to this option shall vest and become exercisable on February 13, 2024, with the remainder vesting in 36 equal monthly installments thereafter.

Remarks:

Officer Title: Vice President, Finance and Corporate Controller